Improving treatment of non-Hodgkin lymphoma (NHL) through pretargeted radioimmunotherapy (PT-RIT) and consolidation veltuzumab (humanized anti-CD20) IgG serotherapy

被引：0
|
作者：
Sharkey, R. M. [1 ,2 ]
Karacay, H. [1 ,2 ]
Johnson, C. R. [1 ,2 ]
Rossi, E. A. [3 ]
McBride, W. J. [4 ]
Chang, C-H [3 ,4 ]
Goldenberg, D. M. [1 ,2 ,3 ,4 ]
机构：
[1] Ctr Mol Med & Immunol, Belleville, NJ USA
[2] Garden State Canc Ctr, Belleville, NJ USA
[3] IBC Pharmaceut Inc, Morris Plains, NJ USA
[4] Immunomedics Inc, Morris Plains, NJ USA
来源：
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS | 2008年 / 23卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
26
引用
收藏
页码：521 / 521
页数：1
相关论文
共 50 条
  • [21] Improved therapy of non-Hodgkin's lymphoma xenografts using radionuclides pretargeted with a new anti-CD20 bispecific antibody
    R M Sharkey
    H Karacay
    C-H Chang
    W J McBride
    I D Horak
    D M Goldenberg
    Leukemia, 2005, 19 : 1064 - 1069
  • [22] Improved therapy of non-Hodgkin's lymphoma xenografts using radionuclides pretargeted with a new anti-CD20 bispecific antibody
    Sharkey, RM
    Karacay, H
    Chang, CH
    McBride, WJ
    Horak, ID
    Goldenberg, DM
    LEUKEMIA, 2005, 19 (06) : 1064 - 1069
  • [23] Anti-CD20 monoclonal antibody therapy for non-Hodgkin's lymphoma
    White, CA
    Weaver, R
    Royston, I
    MINERVA BIOTECNOLOGICA, 1998, 10 (03) : 108 - 116
  • [24] Radioimmunotherapy of B-lineage non-Hodgkin's lymphoma using anti-CD19 and anti-CD20 conjugates.
    Heeger, SW
    Moldenhauer, G
    Flynn, JM
    Egerer, G
    Nikula, T
    Apostolidis, C
    Brechbiel, M
    Haberkorn, U
    Ho, AD
    Haas, R
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 194S - 194S
  • [25] Impact of metabolic and pharmacokinetic variability on dosing methodology for radioimmunotherapy (RIT) in patients with CD20+B-cell non-Hodgkin's lymphoma (NHL).
    Wiseman, GA
    Murray, JL
    Pieslor, P
    Molina, A
    Gordon, LI
    Gaston, I
    Emmanouilides, C
    Multani, P
    Witzig, TE
    White, CA
    JOURNAL OF NUCLEAR MEDICINE, 2003, 44 (05) : 415P - 415P
  • [26] Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-labeled anti-CD20 monoclonal antibody
    Postema, EJ
    Oyen, WJG
    Boerman, OC
    Corstens, FHM
    JOURNAL OF NUCLEAR MEDICINE, 2003, 44 (05) : 853 - 853
  • [27] Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with Zevalin, a 90Y-labeled anti-CD20 monoclonal antibody
    Wiseman, GA
    White, CA
    Witzig, TE
    Gordon, LI
    Emmanouilides, C
    Raubitschek, A
    Janakiraman, N
    Gutheil, J
    Schilder, RJ
    Spies, S
    Silverman, DHS
    Grillo-López, AJ
    CLINICAL CANCER RESEARCH, 1999, 5 (10) : 3281S - 3286S
  • [28] Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-labeled anti-CD20 monoclonal antibody
    Wagner, HN
    Wiseman, GA
    Marcus, CS
    Nabi, HA
    Nagle, CE
    Fink-Bennett, DM
    Lamonica, DM
    Conti, PS
    JOURNAL OF NUCLEAR MEDICINE, 2002, 43 (02) : 267 - 272
  • [29] Application of monoclonal anti-CD20 antibody rituximab in the treatment. of non-Hodgkin's lymphoma
    Mihaljevic, Biljana
    Jankovic, Snezana
    Jakovic, Ljubomir
    Jovanovic, Maja Perunicic
    Andelic, Bosko
    Milosevic, Violeta
    Sretenovic, Aleksandra
    Virijevic, Marjana
    Petrovic, Milan
    VOJNOSANITETSKI PREGLED, 2008, 65 (03) : 229 - 233
  • [30] Characterization of a Novel Humanized Anti-CD20 Antibody with Potent Anti-Tumor Activity against Non-Hodgkin's Lymphoma
    Zhang, Haifeng
    Song, Liping
    Ye, Hongtu
    Hu, Lide
    Liang, Wenlu
    Liu, Datao
    CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2013, 32 (03) : 645 - 654
12345